Vascular Biogenics Ltd. (VBLT) Cut to “Sell” at Zacks Investment Research
Vascular Biogenics Ltd. (NASDAQ:VBLT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
A number of other research analysts have also weighed in on the stock. Roth Capital reissued a “buy” rating and set a $17.00 price target on shares of Vascular Biogenics in a research report on Tuesday, August 16th. HC Wainwright began coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Vascular Biogenics presently has an average rating of “Buy” and a consensus price target of $13.67.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/vascular-biogenics-ltd-vblt-cut-to-sell-at-zacks-investment-research.html
Shares of Vascular Biogenics (NASDAQ:VBLT) opened at 5.00 on Wednesday. Vascular Biogenics has a 12-month low of $2.76 and a 12-month high of $8.18. The company’s market cap is $118.01 million. The firm has a 50-day moving average of $4.77 and a 200-day moving average of $4.09.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. Analysts predict that Vascular Biogenics will post ($0.64) EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Vascular Biogenics during the second quarter valued at $1,844,000. Macquarie Group Ltd. acquired a new position in Vascular Biogenics during the second quarter valued at $1,521,000. First Eagle Investment Management LLC increased its position in Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock valued at $4,256,000 after buying an additional 727,273 shares during the last quarter. Turner Investments L.P. acquired a new position in Vascular Biogenics during the second quarter valued at $1,007,000. Finally, Menta Capital LLC increased its position in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 14.46% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.